Further, we validated the anti-cancer and anti-BCL-2 effects of SM396, SM216, and SM949 along with the initial library (26 compounds) by various in vitro and in vivo assays to identify the mechanisms of the identified BH4 selective inhibitors. The gene discussed is BCL2; the disease is cancer.